BioSpace News Archive

Inflammatix , a pioneering molecular diagnostics company, announced today the appointment of experienced medical device executive Amy Boyle as Chief Operating Officer, effective April 5, 2021.

Medable Inc. today announced $78 million in new funding to fuel advances in the delivery of digital and decentralized clinical trials, accelerating the industry’s shift to patient-centered drug development. The funding was led by Sapphire Ventures , along with new investor Obvious Ventures and follow-on investment from existing investors GSR Ventures , PPD, Inc. (Nasdaq:PPD) and Streamlined Ventures .

MJ Biotech Inc., has shipped its first Purchase Order of its COVID 19 Rapid Test Kit to Namibia, Africa. The Rapid Test Kit is a nasal swab test that produces test results in 10 minutes.

Calyx , the eClinical and Regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced the availability of Calyx CTMS v15.0

- COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its first quarter 2021 earnings release and conference call.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the company’s Phase 1 first-line study of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA)

Grant will work to mobilize and engage Black Americans in cancer risk reduction and contribute to ACS’ mortality goal of reducing cancer death by 40% by 2035

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company.

Cardax, Inc. (OTCQB:CDXI) reported its 2020 results